InvestSMART

Imugene Limited (ASX:IMU)

ALERT: Price-sensitive ASX Announcement for IMU
Current share price for IMU : $0.105 0.005 (5%)+
Announcement
Release
30 Jun 2026 11:45AM
Price at Release
$0.100
Full Release
download
Summary
Imugene Limited reported a significant milestone in its azer-cel Phase 1b trial, noting the first complete response from a patient in the concurrent Bruton Tyrosine Kinase inhibitor (BTKi) cohort. The patient, suffering from Follicular Lymphoma and having previously failed BTKi therapy, achieved a complete response by Day 28 of the treatment. This trial explores the combination of azer-cel, an allogeneic CAR T cell therapy targeting CD19, with BTKi therapy to restore or enhance treatment efficacy. The study is ongoing in multiple sites across the US and Australia, with more patients being enrolled. The BTKi market is significant, valued at approximately US$12 billion in 2025, and azer-cel therapy could present a new pathway for patients with limited options.
Key Points
  • First complete response in concurrent BTKi cohort of azer-cel Phase 1b trial.
  • Patient with Follicular Lymphoma achieves complete response after previously failing BTKi therapy.
  • Azer-cel is an off-the-shelf, allogeneic CAR T cell therapy targeting CD19.
  • Trial conducted across ten US and five Australian sites.
  • Global BTKi market valued at US$12 billion in 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.